Phase 1, Open-Label, Dose Escalation, Safety, and Pharmacokinetics Study of ME-344 as a Single Agent in Patients With Refractory Solid Tumors

BACKGROUND: The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors. METHODS: Patients with refractory...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendell, Johanna C, Patel, Manish R, Infante, Jeffrey R, Kurkjian, Carla D, Jones, Suzanne F, Pant, Shubham, Burris, Howard A, Moreno, Ofir, Esquibel, Vanessa, Levin, Wendy, Moore, Kathleen N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406150/
https://www.ncbi.nlm.nih.gov/pubmed/25411085
http://dx.doi.org/10.1002/cncr.29155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4406150/
https://www.ncbi.nlm.nih.gov/pubmed/25411085
http://dx.doi.org/10.1002/cncr.29155

Ejemplares similares